Research programme: ATRN protein inhibitors - Atrin Pharmaceuticals

Drug Profile

Research programme: ATRN protein inhibitors - Atrin Pharmaceuticals

Alternative Names: Ataxia telangiectasia and Rad3-related protein inhibitors - Atrin Pharmaceuticals; ATRN 502; ATRN 507; ATRN-119

Latest Information Update: 12 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atrin Pharmaceuticals
  • Developer Atrin Pharmaceuticals; University of Pennsylvania
  • Class Small molecules
  • Mechanism of Action ATR protein inhibitors; P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2016 Preclinical trials in Cancer in USA (PO) prior to April 2016
  • 16 Apr 2016 Pharmacodynamics data from preclinical trials in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top